Human and animal studies have shown CXCR1/2 agonists (e.g., CXCL8, CXCL5 in T1D patients, CXCL1 in mice) to be correlated with obesity (12–16) and insulin resistance (96, 97). Here, CXCL8 is linked to type 1 diabetes mellitus.